Stockwinners Market Radar for June 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment sold 211K shares of Exact Sciences today

20:04 EDT Avita Medical announces FDA approval of RECELL in skin defect treatments - AVITA Medical "announced that the U.S. Food and Drug Administration has approved its premarket approval supplement for the use of its RECELL(R) System to treat full-thickness skin defects. The expanded indication represents a broad label of full-thickness skin defects, such as wound injuries after traumatic avulsion, surgical excision, or resection, thereby dramatically expanding the company's market opportunity at least five times. The RECELL System was first approved in the U.S. for the treatment of severe burns in 2018. The system is an autologous cell harvesting device that prepares, produces, and delivers a regenerative cell suspension, Spray-On Skin(TM) Cells, using a small amount of a patient's own skin. The Spray-On Skin Cells contain a combination of single living cells that stimulate healing and repigmentation throughout the wound bed. The PMA supplement received prioritized review through the FDA's Breakthrough Device program. The FDA grants the Breakthrough Device designation to medical devices that provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions. The PMA supplement approval follows the original PMA approval of the RECELL System for the treatment of severe burns in September 2018."

19:42 EDT e.l.f. Beauty director sells $3.94M in common stock - In a regulatory filing, e.l.f. Beauty disclosed that its director Richard Wolford sold 36.8K shares of common stock on June 6th in a total transaction size of $3.94M.

18:25 EDT Campbell Soup CEO: This is the quarter we expected - In an interview on CNBC's Mad Money, Mark Clouse said, "We feel very good about both of our businesses." The businesses have been resilient and performed well, according to Clouse. "Our supply chain is the best in the industry," he noted. There has been some pressure on the meals and beverage business. The soup business has been a "strong performer," and snacks had a "home run" quarter, he said. He's seeing moderation in inflation, but expects that it's not going away.

17:36 EDT Iqvia exec Knightly sells 5,820 common shares - In a regulatory filing, Iqvia Holdings president of corporate strategy and enterprise networks Kevin Knightly disclosed the sale of 5,820 common shares of the company on June 5 at a price of $201.89 per share.

17:19 EDT Privia Health to replace Ruth's Hospitality in S&P 600 at open on 6/14 - Darden Restaurants (DRI) is acquiring Ruth's Hospitality Group (RUTH) in a deal expected to be completed soon pending final conditions.

17:09 EDT Google Cloud teams with Mayo Clinic 'to transform healthcare with generative AI' - Google Cloud announced a collaboration with Mayo Clinic to transform healthcare with generative AI, starting with Enterprise Search in Generative AI App Builder or Gen App Builder, to improve the efficiency of clinical workflows, make it easier for clinicians and researchers to find the information they need, and ultimately to help improve patient outcomes. In addition, Google Cloud announced today that its Enterprise Search on Gen App Builder is now ready to support HIPAA compliance. Healthcare professionals use information from various sources, including medical records, research papers, and clinical guidelines to help them with everything from definitions of conditions to diagnoses and treatment options. However, healthcare data is often stored in many different formats and locations, which can make it difficult to find the information clinicians need when they need it. Enterprise Search in Gen App Builder unifies data across dispersed documents, databases, and intranets, making it easier to search, analyze, and identify the most relevant results. Google Cloud is collaborating with Mayo Clinic to transform healthcare with gen AI, starting with enterprise search. "Generative AI has the potential to transform healthcare by enhancing human interactions and automating operations like never before," said Thomas Kurian, Google Cloud CEO. "Mayo Clinic is a world leader in leveraging AI for good, and they are a critical partner as we identify responsible ways to bring this transformative technology to healthcare." Reference Link

16:57 EDT Scotiabank raises prime lending rate to 6.95%-6.7% - Scotiabank announced that it is increasing its Canadian dollar prime lending rate to 6.95% from 6.7%, effective June 8, 2023.

16:47 EDT Primoris receives awards with over $650M in combined value - Primoris received several awards with a combined value over $650M by the company's Energy Segment. These awards spread across six states and include a number of projects from natural gas power generation plants to highways and bridges. The awarded projects are all expected to begin work in Q2 and Q3.

16:37 EDT Nike CFO sells $990K in common stock - In a regulatory filing, Nike disclosed that its CFO Matthew Friend sold 9.2K shares of common stock on June 5th in a total transaction size of $990K.

16:35 EDT Digital World Acquisition board approves extension for combination consumation - Digital World Acquisition announced that its Board of Directors approved an extension of the date by which the Company would be required to consummate a business combination from June 8 to September 8 .

16:32 EDT PainReform discloses supplier FDA deficiency notice in ph3 trial of PRF-110 - PainReform provided a regulatory update on the second part of its Phase 3 clinical trial of PRF-110 in patients undergoing bunionectomy surgery. The Company's supplier of the API has received a deficiency notice from the FDA related to its Drug Master File. The DMF is the file on record with the FDA representing the manufacturing process and facility for the production of the API. As a result, the second part of the Phase 3 trial is expected to commence once the required information has been provided by the supplier to the FDA and the deficiency notice has been resolved. None of the issues raised relate to the Company's PRF-110 product. CEO Ilan Hadar stated, "Although we encountered what will likely be a delay in starting the second part of the Phase 3 trial, we are working closely with our API supplier to ensure the matter is resolved in the most expedient manner possible. These circumstances were out of our control, but we believe our supplier is taking the necessary steps, which should enable us to commence the second part of the trial in as short a timeframe as possible. We look forward to providing near-term updates about the timeline as soon as practicable. We do not believe that the deficiency noted has or would have any risk to patients. Moreover, it is important to note that Ropivacaine, the active drug used in PRF-110, has been shown to be a safe, well-tolerated, and well-characterized local anesthetic for many years. We are therefore confident of the safety and quality of our product and the outlook for this program. We believe PRF-110 holds tremendous promise and will ultimately contribute to a reduction in the frequency of opiate use following surgical procedures, thereby lessening the risk of opiate abuse disorder and ultimately saving lives."

16:27 EDT Toast co-President sells $1.29M in common stock - In a regulatory filing, Toast disclosed that its co-President Stephen Fredette sold 57.8K shares of common stock on June 6th in a total transaction size of $1.29M.

16:20 EDT Greif sees FY23 adjusted EBITDA $780M-$830M

16:19 EDT Semtech falls 5% to $21.33 after Q1 results and guidance

16:18 EDT HashiCorp targets cuts in discretionary spending, to cut 8% of workforce - HashiCorp also announced targeted cuts in discretionary spending and a workforce reduction of approximately 8%. "We are responding to the current customer and economic environment with proactive actions to lower our ongoing costs. This was a difficult decision that we don't take lightly, and I am deeply disappointed to lose many valued colleagues," said McJannet. "I believe, however, that after these actions we are better positioned for our opportunity." "Looking at key financial metrics from our first quarter, we've continued to make progress improving the operating efficiency of HashiCorp, and saw continued growth in customers with equal to or greater than $100,000 ARR," said Navam Welihinda, CFO, HashiCorp. "We are committed to reaching our breakeven target of the second half of fiscal year 2025 and are focused on driving efficiency while preserving our long-term opportunity."

16:18 EDT Nikola adjourns Annual Meeting of Stockholders to July 6 - Nikola announced that its 2023 Annual Meeting of Stockholders has been adjourned to July 6, 2023 at 1 p.m. Pacific Time to allow stockholders additional time to vote FOR Proposal 2.

16:16 EDT Universal Health Realty raises quarterly dividend to 72c per share - Universal Health Realty announced that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of 72c per share on June 30 to shareholders of record as of June 20.

16:14 EDT GameStop falls after firing CEO, naming Ryan Cohen Chairman - Shares of GameStop are moving lower after the company disclosed that its board has elected Ryan Cohen as Executive Chairman, effective immediately. Cohen's responsibilities "include capital allocation and overseeing management," GameStop said in a statement. It added, "In conjunction, the Company's former CEO has been terminated." Shares of GameStop are down 7% to $24.27 in after-hours trading.

16:13 EDT Tupperware Brands receives listing non-compliance notice from NYSE - Tupperware Brands received a notice from the NYSE on June 1 indicating the company is not in compliance with the NYSE Listed Company Manual because the company's average global market capitalization over a consecutive 30 trading-day period was less than $50M and, at the same time, its last reported stockholders' equity was less than $50M, and the average closing price of the company's common stock was less than $1.00 over a consecutive 30 trading-day period. The Notice has no immediate effect on the listing of the common stock on the NYSE. Tupperware plans to notify the NYSE that it intends to bring the company into compliance with these listing standards within the required cure periods. The company has 45 days from receipt of the Notice to submit a business plan advising the NYSE of the definitive action(s) the company has taken or is taking to regain compliance with the listing standard, taking into consideration the additional stock price deficiency. If the NYSE approves the company's business plan, the company's shares will continue to be listed and traded on the NYSE during the 18-month cure period, subject to its compliance with other NYSE continued listing standards. The company will be subject to quarterly monitoring by the NYSE for compliance with the business plan.

16:11 EDT Floor & Decor acquires Salesmaster Flooring Solutions - Floor & Decor "announced its wholly owned subsidiary Spartan Surfaces had acquired Salesmaster Flooring Solutions, a leading flooring and installation supplies distributor servicing the Northeastern part of the United States. Headquartered in Deer Park, New York, the company has approximately 80 employees and will operate as a part of Spartan Surfaces. The transaction closed June 7 and is not expected to have a material impact on Floor & Decor's fiscal 2023 second quarter or full year 2023 financial results. Terms of the transaction were not disclosed."

16:11 EDT Smartsheet falls 12% to $42.93 after Q1 results and guidance

16:08 EDT Smartsheet reports Q1 billings $215.5M, up 20% from last year - In Q1: Dollar-based net retention rate was 123%; Number of all customers with annualized contract values ("ACV") of $100,000 or more grew to 1,569, an increase of 42% year over year; Number of all customers with ACV of $50,000 or more grew to 3,343, an increase of 33% year over year; Number of all customers with ACV of $5,000 or more grew to 18,483, an increase of 16% year over year; Average ACV per domain-based customer increased to $8,520, an increase of 18% year over year.

16:06 EDT Gladstone Commercial executes 11-year, 1-month lease of Florida property - Gladstone Commercial Corporation announced that it has executed an 11-year, 1-month lease with Moss & Associates for the entirety of its 119,224 SF office building in Fort Lauderdale, Florida, commencing on June 1. Moss had been subleasing approximately 40% of the building and had previously executed a 5-year, 4-month deal beyond the sublease term for that space. It will now expand into the full building on a longer-term direct lease with Gladstone Commercial.

16:05 EDT Emcor CEO Guzzi sells 6,829 common shares - In a regulatory filing, Emcor Group chairman, president, and CEO Anthony Guzzi disclosed the sale of 6,829 common shares of the company on June 6 at a price of $175.02 per share.

16:03 EDT DLocal appoints Sergio Fogel co-president and Chief Strategy Officer - DLocal Limited announced that Sergio Fogel was appointed as co-president and Chief Strategy Officer. Fogel co-founded dLocal and has been an active member of the board, providing strategic vision and hands-on support on key business initiatives since the company's inception. His appointment as co-president and Chief Strategy Officer formalizes the role he has been carrying out alongside CEO Sebastian Kanovich and co-president and COO Jacobo Singer.

15:00 EDT Ball Corp. CEO says April 'soft,' May 'was better' - Asked during the Deutsche Bank Industrials and Materials Summit about what the company is seeing into the summer months and season in terms of promotional activity, Ball Corp. CEO Dan Fisher replied in part: "So we didn't anticipate and you can refer back to our earnings call notes at the end of the first quarter. We haven't expected much in terms of the promotional landscape on the nonalcohol products and it's playing out that way right now. And part of the reason is when we look at the landscape of the comp, the comps for our large customers in those categories, they've got ample headroom here up until tail end of Q3 and Q4 is where we'll have tougher comps from a pricing dynamic versus what they've laid in over the course of last year. So if we are thinking anything, I don't think it will be anywhere near what we've seen historically prior to COVID, but there will be tactical and regional, we believe, executions against some promotional activity, but it won't look anything near as significant as maybe the kind of the buy one, get 1 free typical behavioral patterns that you may have seen during -- especially during the the Memorial Day, fourth of July, Labor Day time sequencing those patterns. Memorial Day, there was a little bit, but again, not much. It was really tactical in nature. I think April was soft in May was better, but I'm not entirely sure if May was anything that we weren't already anticipating... there's more volume in the nonalcoholic space just in terms of the number of cans and the segmentation. So it's more important for us across the industry. We have a sizable beer portfolio more than our competitors. So us versus our competitors, it matters to us. And there is promo and the problem is it's promo on product that's not selling. So by virtue of that, it's really not -- it's not having the intended effect. It's not hugely important at this point. At some point, you will want to see the underpinnings of growth supported by some pricing behaviors. And volume still, at the end of the day, matters, matters for us, matters for our customers, matters for the brewers."

14:05 EDT Art's Way announces intention to discontinue Tools business - Art's Way Manufacturing announced that it intends to discontinue the operations of its Tools segment in the third quarter of its 2023 fiscal year. Operations of the Tools segment are under Ohio Metal Working Products/Art's Way Inc. dba American Carbide Tool, a wholly owned subsidiary of the company, and specializes in the manufacturing of standard single point brazed carbide tipped tools as well as PCD and CBN inserts and OEM tools. "The intended action is part of the company's ongoing focus of efforts and resources on the business segments that have historically been more profitable and that are expected to present greater long-term stockholder returns. The company plans to fulfill its current backlog commitments to customers and subsequently pursue an orderly sale of the assets associated with the Tools segment, including real estate, equipment and inventory. Proceeds from the liquidation of ACT assets will be used for the retirement of debt and to make operational improvements in the Agricultural Products segment. The company anticipates incurring charges associated with this divestiture until the process is complete, likely in the fiscal year ending November 30, 2023. The union representative has been notified of the expected closure, which will affect approximately 15 employees," Art's Way stated. "Our Tools segment has historically generated losses causing us to consider multiple options for the business. After careful consideration and testing the market for the feasibility of a sale of the business unit, the decision was ultimately made to discontinue that business in order to focus on our profitable operations to deliver additional stockholder value. We would like to thank the employees for their work in this business and regret that this decision impacts them negatively. This decision was difficult but is a necessary step in positioning our business for the long-term," added Art's Way Manufacturing CEO, David King.

13:58 EDT Aleafia, Red White & Bloom enter binding letter agreement for combination - Red White & Bloom Brands (RWBYF) and Aleafia Health (ALEAF) announced that the Company and Aleafia have entered into a binding letter agreement on June 6, 2023 whereby the Company has agreed to acquire Aleafia and its subsidiaries in a business combination transaction. Under the terms of the Letter Agreement, each outstanding common share in the capital of Aleafia will be exchanged for 0.35 of a common share in the capital of the Company, subject to customary adjustment. Upon the completion of the Proposed Transaction, existing RWB shareholders are expected to own approximately 76% of the Combined Company resulting from the Proposed Transaction and Aleafia shareholders are expected to own approximately 24% of the Combined Company. The Letter Agreement provides for the parties to enter into a definitive arrangement agreement setting out the final terms and conditions of the Proposed Transaction, at which time additional information will be provided in a subsequent press release. Key Business and Transaction Highlights: Expected to create an opportunity to collaboratively launch RWB and Aleafia's premium brands across multiple product categories into well-established distribution and retail networks throughout North America providing approximately 3,000 retail locations in active markets including Michigan, Florida, California, Arizona, Missouri, and select provinces in Canada including Ontario, British Columbia, Alberta, Manitoba, and Saskatchewan and Europe. The Combined Company is anticipated to realize synergies of approximately $10 million as the Combined Company will aim to: leverage RWB's supply chain and manufacturing competencies, increase each of RWB and Aleafia's respective economies of scale with the introduction of incremental premium product volumes, and optimize Aleafia's post-close operations as a subsidiary of RWB versus a standalone publicly traded entity. The Proposed Transaction is expected to be completed by way of a court-approved plan of arrangement under the Business Corporations Act. Under the terms of the Letter Agreement, RWB will acquire all of the issued and outstanding Aleafia Shares in exchange for RWB Shares on the basis of the Exchange Ratio. Outstanding options and warrants to purchase Aleafia Shares will become exercisable to acquire RWB Shares on the same terms and conditions, on the basis of the Exchange Ratio. Outstanding restricted and deferred share units of Aleafia will be settled upon closing in RWB Shares on the basis of the Exchange Ratio. The Proposed Transaction will require the approval of: two-thirds of the votes cast by shareholders of Aleafia, and, if required, a simple majority of the votes cast by minority Aleafia shareholders in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, at a special meeting of Aleafia shareholders expected to take place in the third quarter of 2023; debentureholders of the requisite percentage of the principal amount of each series of Aleafia Convertible Debentures; and (c) if required, RWB shareholders at a special meeting of RWB shareholders expected to take place in the third quarter of 2023. Completion of the Proposed Transaction will be subject to customary closing conditions and receipt of necessary court and regulatory approvals, including stock exchange approval. Subject to receipt of all necessary approvals, the Proposed Transaction is expected to close by no later than 5:00 p.m. on October 31, 2023. The Letter Agreement provides for the parties to enter into a definitive arrangement agreement setting out the final terms and conditions of the Proposed Transaction on or before July 31, 2023. The Letter Agreement contains, and the arrangement agreement will continue to contain, standard non-solicitation and superior proposal provisions and a break fee of C$2 million. The Letter Agreement includes, and arrangement agreement will continue to include other provisions such as conditions to closing the Proposed Transaction, and representations and warranties and covenants customary for arrangement agreements. Further details with respect to the Proposed Transaction will be included in the arrangement agreement and in an information circular to be mailed to Aleafia shareholders in connection with the Aleafia Meeting and to holders of Aleafia Convertible Debentures, as applicable, and to RWB shareholders in connection with the RWB meeting/

13:44 EDT North American rail traffic down 4.2% for the week ending June 3 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending June 3. "Roughly half of U.S. intermodal shipments are related to international trade, so what happens at ports is extremely important to railroads," said AAR Senior Vice President John T. Gray. "U.S. port volumes, especially on the West Coast, have already been trending down for months and are a major reason why rail intermodal volumes have been on the decline in 2023." Total U.S. weekly rail traffic was 439,601 carloads and intermodal units, down 5.7% compared with the same week last year. Total carloads for the week ending June 3 were 219,289 carloads, up 0.4% compared with the same week in 2022, while U.S. weekly intermodal volume was 220,312 containers and trailers, down 11.1% compared to 2022. North American rail volume for the week ending June 3, on 10 reporting U.S., Canadian and Mexican railroads totaled 321,168 carloads, up 0.5% compared with the same week last year, and 302,681 intermodal units, down 8.8% compared with last year. Total combined weekly rail traffic in North America was 623,849 carloads and intermodal units, down 4.2%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Greenbrier (GBX),Trinity Industries (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:18 EDT ITT CFO says performance in Q2 'probably better than what we were expecting' - Speaking at the UBS Global Industrials and Transportation Conference, ITT CFO Emmanuel Caprais stated, according to a transcript of the event: "Now moving on to Q2, maybe to give you a quick update. So IP continues to do well from the revenue -- so we expect IP to be above 20% in terms of revenue growth for the quarter versus prior year. And what's really interesting with a book-to-bill that's going to be largely above not only we're growing significantly the top line, but our orders are also growing faster than the top line. In MT, the Friction OE outperformance is back to historic levels. So we had said in Q1 that we were around 100 basis points -- a little more than 100 basis points of our performance. In Q2, sequentially, we're improving. And so we're back to the historic level 800 to 900 basis points of outperformance. And a lot of it is coming from China... From a CCT standpoint, so we continue to see strong aero demand from an order standpoint. So we expect aero orders growth to be around -- to be high teens -- in the high-teen percentage. Supply chain is still a headwind. Aero supply chain is a mess, and it's impacting us... In terms of MT, MT is doing well. Margins are expected to improve sequentially compared to the nearly 15% we had reported in Q1. So this is very positive. And this is despite aftermarket activity that is down. We expect aftermarket to be down in the low double digits in Q2 versus prior year. And for the full year, to be down around 5% to 8%. So that means that the second half of the year is going to -- we're still going to continue to see difficulties. IP from a margin standpoint continues to perform really well. And CCT, as we said, is probably going to be flat sequentially because of the decline in orders that are converting now in terms of revenue. From a pricing productivity standpoint, so we really see the impact of the pricing ramping up. Pricing is ramping up in MT, it's ramping up in IP. And then for CCT, we're going to start seeing some benefits in June also. The pricing is good. Volume is going to help us also. We have strong volume, as I mentioned, in IP, a little less so in CCT. But I've said it is going to drive segment level margin expansion. And so we expect our EPS to be above 20%, growing above 20% in Q2 compared to the prior year. And then finally, from a free cash flow standpoint, so free cash flow has been doing really well... The first 2 months of Q2, we've already generated more than what we generated for the entire Q1. So collection momentum is up. We're starting to see some progress on the inventory. So we're really happy with the free cash flow, especially because debt is so expensive. So we're happy with the progress we're making on cash. And from a capital deployment standpoint, we did Micro-Mode in May. We also were active in the market, and we did some repurchases so far in Q2. And so -- and then as I mentioned, the funnel of M&A is progressing. So I would say, good performance, strong performance in Q2. And so probably better than what we were expecting. For the rest of the year, we still have uncertainties that we're dealing with. But I would say Q2 is very, very encouraging."

12:25 EDT Volvo unveils fully electric SUV EX30 - Volvo unveiled the EX30, a fully electric small SUV designed to have the smallest carbon dioxide footprint of any Volvo car to date. "Revealed to the world today in Milan, Italy and available to order now in selected markets, the EX30 is our first small premium SUV and expands our constantly growing, all-electric offering to four models," the company said. " As the market is rapidly moving towards full electrification, the EX30 will help us capture growing demand for fully electric cars in a fast-growing segment." Volvo also noted that, starting next year, the EX30 will also become available as a Cross Country variant. "The fully electric EX30 might be our smallest ever SUV, but it's a big deal for our customers and a big deal for us as a company," said Jim Rowan, our chief executive. "We like to say the EX30 is small yet mighty, because it delivers on everything you'd want from a Volvo but in a smaller package. Like any Volvo, it's an outstanding product which is safe and designed around people and their needs."

12:08 EDT Quotient Technology enters cooperation agreement with Engaged Capital - Quotient Technology announced plans to refresh its Board of Directors in connection with a cooperation agreement with Engaged Capital. The Company will nominate Kate Vanek, Global Chief Operating and Financial Officer of True Talent Advisory, and Tracey Figurelli, Director of Andra Partners, to stand for election to the Company's Board of Directors at the 2023 Annual Meeting of Stockholders. In addition, David Oppenheimer, Jody Gessow and Lorraine Hariton will not stand for re-election, and Alison Hawkins and Eric Higgs will resign effective as of the 2023 Annual Meeting. With these changes the Board will be reduced to seven directors, six of whom will be independent, following the 2023 Annual Meeting. Quotient's 2023 Annual Meeting has been scheduled for August 3, 2023. The Company notes that as previously disclosed, the declassification of its Board was approved at the Company's 2022 Annual Meeting and the Board will be de-staggered fully in 2024. Pursuant to the cooperation agreement, Engaged Capital has agreed to a customary standstill and vote support agreements. The cooperation agreement between the Company and Engaged Capital will be filed on a Form 8-K to be filed with the Securities and Exchange Commission.

12:00 EDT Natuzzi falls -6.7% - Natuzzi is down -6.7%, or -47c to $6.53.

12:00 EDT United Natural Foods falls -17.6% - United Natural Foods is down -17.6%, or -$4.84 to $22.73.

12:00 EDT Getty Images rises 14.9% - Getty Images is up 14.9%, or 83c to $6.41.

11:29 EDT Tigo Energy Inc trading resumes

11:13 EDT Meta Platforms expands Meta Verified to India - In a company blog post, Meta said, "We're expanding our test of Meta Verified to India after seeing good results from our early testing in several countries globally. We'll also continue honoring verified badges that were granted previously based on existing criteria. To help up-and-coming creators grow their presence more quickly on our apps, in February we announced that we'll begin testing a new offering called Meta Verified. It is a subscription bundle on Instagram and Facebook that includes a verified badge that authenticates your account with government ID, proactive account protection and access to account support. Since our initial test of Meta Verified in Australia and New Zealand, we've made a few adjustments based on learnings, including the removal of increased reach for additional test countries. This continues to be the approach for India. We're exploring elements to add to the subscription as we roll out to more places and will share more when we're ready." Reference Link

11:04 EDT Electronic Arts announces multi-year partnership renewal with CONMEBOL - Electronics Arts and CONMEBOL, the governing body of football in South America, have announced a multi-year partnership renewal with EA SPORTS. "This partnership will see EA SPORTS remain CONMEBOL's exclusive Sports Video Gaming Partner, and ensure South America's most prestigious football competitions will continue to be shared with millions of fans around the world as part of the new EA SPORTS FC brand ecosystem," the company stated.

11:01 EDT Blue Apron announces 1-for-12 reverse stock split - Blue Apron announced that its board of directors approved a reverse stock split of the company's Class A common stock at a ratio of 1-for-12. Earlier on June 7, at the company's annual meeting of stockholders, the company's stockholders approved a reverse stock split of the company's Class A common stock at a split ratio of between 1-for-5 and 1-for-20. The reverse stock split is expected to be effective after market close on June 7. The company's Class A common stock will begin trading on a split-adjusted basis on the New York Stock Exchange at the market open on June 8. Once effective, the reverse stock split will reduce the number of shares of Class A common stock issued and outstanding from approximately 76M to approximately 6M.

10:34 EDT Citizens Financial to cease originating indirect auto loans - Citizens Financial Group will no longer originate indirect auto loans, effective July 1, 2023, as part of its strategy to optimize its balance sheet and emphasize relationship-based lending. Citizens will retain and continue to service existing auto loans on its balance sheet. In third quarter 2022, Citizens began to reduce the number of active dealer relationships and de-emphasize its auto loan origination volume. At March 31, 2023, Citizens had $11.5B of auto loans outstanding, down 6.5% from December 31, 2022 and down 20.1% from March 31, 2022. The centralized servicing operations will continue to provide excellent service to our auto loan customers.

10:02 EDT Twilio announces expanded partnership with Google Cloud - Twilio (TWLO) and Google Cloud (GOOGL) announced an expansion of their long-standing partnership to bring Google Cloud generative artificial intelligence to Twilio's customer engagement products to improve experiences for millions of end users. "For more than a decade, Google Cloud and Twilio have been working together to innovate in the customer engagement space. Today, the companies are exploring new ways to infuse generative AI into Twilio Flex and across the Twilio Customer Engagement Platform, with the shared goal of transforming how brands personalize their customer interactions," the companies stated.

10:00 EDT Campbell Soup falls -7.4% - Campbell Soup is down -7.4%, or -$3.72 to $46.87.

10:00 EDT Nerdy rises 9.5% - Nerdy is up 9.5%, or 26c to $3.01.

10:00 EDT Yext rises 31.5% - Yext is up 31.5%, or $3.02 to $12.62.

09:51 EDT Transcontinental CEO Peter Brues departs, Thomas Morin succeeds - The Board of Directors of Transcontinental announced the appointment of Thomas Morin as President and CEO, effective immediately. Mr. Morin previously served as President of TC Transcontinental Packaging, beginning in 2019. He replaces Peter Brues, who is leaving the Company. The Board also announced expanded roles for Isabelle Marcoux and Donald LeCavalier. Isabelle Marcoux, Chair of the Board, becomes Executive Chair of the Board, with oversight of Strategy and Corporate Development. CFO Donald LeCavalier will take on an expanded role as Executive Vice President and CFO.

09:47 EDT Campbell Soup falls -8.4% - Campbell Soup is down -8.4%, or -$4.24 to $46.35.

09:47 EDT Getty Images rises 8.4% - Getty Images is up 8.4%, or 47c to $6.05.

09:47 EDT Yext rises 28.2% - Yext is up 28.2%, or $2.71 to $12.31.

09:36 EDT Bone Biologics Corp trading halted, volatility trading pause

09:23 EDT Baudax Bio announces topline results from Phase 2 BX1000 trial - Baudax Bio announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery. Additional analyses of electromyography of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a completed clinical trial of 80 adult patients who had elective surgery utilizing total intravenous anesthesia. A total of 81 patients were randomized to the four treatment groups. One patient discontinued early and did not receive a study drug. A total of 80 patients were treated. Each BX1000 dose cohort had 20 evaluable patients and the rocuronium cohort had 19 evaluable patients. The primary efficacy endpoint of the study was the proportion of patients that met criteria for Good or Excellent intubating conditions using a standardized scale. All patients, across regimens, met the primary efficacy criteria. Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population. The additional EMG data showed a clear dose response for BX1000 on maximum T1 suppression, with comparable results for the 1.5x ED95 dose of BX1000 and the 2X ED95 dose of rocuronium. An equivalent "time to 80% NMB" was also observed between the highest dose level for BX1000 and rocuronium. Recovery measures showed equivalent time for "full recovery" *for the highest dose of BX1000 and rocuronium, but with tighter, thus more predictable, margins for BX1000.

09:21 EDT American Lithium enters agreement to spin out Macusani Uranium Project - American Lithium entered into a definitive arrangement agreement with Friday's Dog Holdings, a public company currently listed on the TSX Venture Exchange and to be renamed International Uranium, dated June 6, 2023, pursuant to which it will transfer ownership of its Macusani Uranium Project. In accordance with the terms of the Arrangement Agreement, the Company will transfer ownership of a wholly owned Peruvian subsidiary which holds the mineral concessions comprising the Macusani Project to International Uranium. In connection with the Transaction, International Uranium will consolidate its outstanding share capital of 84,069,352 common shares on the basis of one post-Consolidation common share for every four-and-one-half pre-Consolidation shares resulting in 18,682,078 being outstanding and will issue to the Company 80,000,000 post-Consolidation common shares in consideration for the Macusani Project. On Closing, International Uranium has committed to have a minimum of C$5,000,000 in available cash and concurrently with the entering into of the Arrangement Agreement has announced a brokered private placement of subscription receiptsled by Eight Capital and National Bank Financial Inc. with a syndicate that includes Canaccord Genuity Corp., Clarkson Securities AS and TD Securities raise gross proceeds of C$15,000,000. On a pro forma basis, there is expected to be approximately 128,862,078 common shares of International Uranium outstanding upon completion of the Transaction assuming the minimum amount is raised in the Concurrent Financing. International Uranium will also reconstitute its board of directors and management to consist of nominees of the Company. Through the Transaction, the Company aims to recognize the market value of the advanced, development stage Macusani Project for the benefit of its shareholders by creating an independent, well financed, uranium-focused, publicly traded company, International Uranium, which will drive this large-scale uranium project forward through feasibility and beyond. International Uranium will immediately benefit from the work done to date by American Lithium on the Macusani Project and in particular a highly robust PEA, advanced metallurgy and drill permits which have been filed for the next phases of drilling and are expected to be finalized shortly. The Transaction will also enable American Lithium to better focus all its efforts on advancing its two premier lithium projects, TLC in Nevada, and Falchani in Peru.

09:17 EDT NeuroMetrix says DPN-check, Sudoscan predict all-cause mortality in diabetics - NeuroMetrix, noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled "Abnormal combined diabetic peripheral neuropathy DPN -check and SUDOSCAN results predict all-cause mortality in people with diabetes: The Sheffield prospective study."= The study prospectively followed 245 individuals with diabetes for 7-years following screening for peripheral neuropathy. The screening tests included a structured clinical exam , the Semmes-Weinstein Monofilament test that is a subjective, clinical test for DPN, a device that measures autonomic nerve function, and DPNCheck. DPNCheck and Sudoscan are complementary validated point-of-care tests for DPN. The initial cross-sectional screening results were previously published and showed that DPNCheck was the most accurate individual test for DPN.

09:13 EDT Warner Bros. Discovery: Chris Licht steps down as CEO of CNN Worldwide - Warner Bros. Discovery announced that Chris Licht, Chairman and CEO of CNN Worldwide, has stepped down, effective immediately. As the company undertakes an active search for a replacement, it has put in place a strong interim leadership team comprising seasoned programming leaders Amy Entelis, EVP of talent and content development, Virginia Moseley, EVP of editorial, and Eric Sherling, EVP of US programming, as well as David Leavy, chief operating officer, on the commercial side.

09:11 EDT Nasdaq says Borqs Technologies eligible for extension till Oct 24 for bid price - Borqs Technologies announces that The Nasdaq Stock Market has provided written notice dated June 2 that the Company is eligible for an extension until October 24 to regain compliance with Nasdaq's minimum $1 bid price requirement, as set forth in Nasdaq's Listing Rule 5550(a)(2) . The Company has explained to the Nasdaq Panel that the sale of our solar subsidiary, Holu Hou Energy may bring forth a significant liquidity position and can positively affect our stock price."The Company believes that since HHE has several hundred million dollars of PPA contract bookings, the sale of our equity in HHE may generate a significant amount of cash for the Company," said Pat Chan, the Company's CEO. The Company has provided written notice, as required by Nasdaq, of our intention to cure the deficiency during the period by the sale of our subsidiary and also by effecting a reverse stock split, if necessary. Compliance can be attained during this additional time period if the closing bid price of the Company's security is at least $1 per share for a minimum of 10 consecutive business days before October 24.

09:09 EDT American Power Group signs marketing agreement with Nat G CNG Solutions - American Power Group has signed a collaborative Vehicular Dealer/Installer Agreement with Nat G CNG Solutions to market and service APG's next generation of low carbon V6000 Dual Fuel diesel engine conversion solutions for existing heavy-duty Class 8 trucks.

09:07 EDT Wrap Technologies to introduce BolaWrap solution to education institutions - Wrap Technologies announced its strategic initiative to introduce the BolaWrap solution to educational institutions across the United States. This program aims to address the pressing issue of mental illness among college students and provide a comprehensive solution to enhance campus safety. With the rise of mental health challenges on college campuses, students are increasingly experiencing stress and anxiety. A groundbreaking study published by PLOS.org revealed that almost 37% of college students studied had diagnosable mental health disorders, contributing to serious and violent behaviors. Recognizing the urgency of this issue, Wrap Technologies aims to equip educational institutions with effective tools to maintain order and protect their students and staff. Wrap Technologies will be showcasing its cutting-edge BolaWrap solution at the upcoming national conference of the International Association of Campus Law Enforcement Administrators on June 27th in Orlando, Florida. This demonstration will provide attendees with the opportunity to witness BolaWrap in action and understand its potential to transform campus safety. The showcase reflects Wrap's commitment to innovative solutions and its prominent role in the public safety market.

09:06 EDT Micron announces volume production availability of 96GB DDR5 RDIMMs - Micron Technology announced volume production availability of high-capacity 96GB DDR5 RDIMMs in speeds up to 4800MT/s, which have double the bandwidth compared to DDR4 memory. By unlocking the next level of monolithic technology, the integration of Micron's high-density memory solutions empowers artificial intelligence and in-memory database workloads and eliminates the need for costly die stacking that also adds latency. Micron's 96GB DDR5 RDIMM modules are qualified with 4th Gen AMD EPYC processors. Additionally, the Supermicro 8125GS - an AMD-based system - includes the Micron 96GB DDR5 modules and is an excellent platform for high-performance computing, artificial intelligence and deep learning training, and industrial server workloads.

09:05 EDT AppFolio launches AI capabilities, affordable housing solution - AppFolio introduced a host of new capabilities to better serve property management customers and their residents. Innovations include AppFolio Realm, uniting all of AppFolio's established AI-powered capabilities and a number of transformational new additions in a common suite, and an affordable housing solution enabling property managers to more efficiently manage affordable housing units. AppFolio also announced new additions to its rapidly growing AppFolio Stack Marketplace, which allows users to seamlessly integrate specialized point solutions with AppFolio's centralized property management software platform.

09:04 EDT V2X awarded a position on the TSA IV program with the Air Force - V2X was awarded a position on the Training Systems Acquisition IV, or TSA IV, program with the U.S. Air Force. The multiple award, indefinite-delivery/indefinite-quantity contract vehicle is valued up to $32.5B over ten-years, including all option periods. The contract aids in the development, installation, and long-term support of cutting-edge training systems designed for aircrew, maintenance personnel, and system-specific training. These systems are instrumental in enhancing global warfighter training efforts.

09:03 EDT Vistagen announces results from exploratory Phase 2A study of PH80 - Vistagen announced that PH80, one of the Company's five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the acute treatment of hot flashes in women diagnosed with menopausal hot flashes. The randomized, double-blind, placebo-controlled exploratory Phase 2A clinical study of PH80 was designed to explore the efficacy, safety, and tolerability of intranasal administration of PH80 for the acute management of menopausal hot flashes in women. In the study, PH80 nasal spray containing epoxyestrenolone 0.8 micrograms/50 microliters was self-administered by subjects intranasally, two sprays in each nostril up to four times daily, as-needed for four consecutive weeks. One additional dose was allowed at night if subjects were awakened by hot flashes. Through the course of the study, subjects recorded the number, severity, disruption in function, and sweating related to hot flashes. PH80 was well-tolerated with no serious adverse events, and the adverse event profiles were comparable between PH80 and placebo. All 36 subjects completed four weeks of treatment and no subject discontinued participation in the study as a result of adverse events. PH80 induced significant reduction in the daily number of hot flashes compared to placebo at the end of the first week of treatment, and the improvement was maintained through each treatment week until the end of the treatment period. At baseline, subjects reported a mean daily number of hot flashes of 7.7 and 8.0. After one week of treatment, the number of hot flashes dropped to 2.8 and 6.4 and after four weeks of treatment the number of hot flashes dropped to 1.5 and 5.1. PH80 treatment also significantly reduced the severity, disruption in function, and sweating related to hot flashes during the treatment period as compared with placebo.

09:02 EDT Johnson Controls increases dividend 1c to 37c - The board of directors of Johnson Controls International has approved a quarterly dividend of 37c per share of common stock, payable on July 14 to shareholders of record at the close of business on June 20. This represents a 1c cent increase over the previous quarterly dividend.

09:00 EDT SentinelOne launches new virtual data center in Australia - SentinelOne announced the launch of a new virtual data center in Australia. The deployment, which comes on the heels of the company achieving Protected IRAP status for its Singularity XDR platform, will aid local government agencies and organizations in complying with data sovereignty requirements and bolstering the nation's cyber defenses, the company said in a statement.

08:55 EDT Capital Southwest announces offering of notes - Capital Southwest announced the commencement of a registered public offering of unsecured notes due 2028. The Notes are expected to be listed on the Nasdaq Global Select Market under the trading symbol "CSWCZ" within 30 days of issuance. Capital Southwest intends to use the net proceeds from this offering to repay a portion of the outstanding indebtedness under its senior secured revolving credit facility. Oppenheimer & Co. Inc., B. Riley Securities, Inc., Janney Montgomery Scott LLC and Ladenburg Thalmann & Co., Inc. are serving as joint book-running managers for this offering. InspereX LLC, William Blair & Company L.L.C. and ING Financial Markets LLC are acting as co-managers for this offering.

08:51 EDT BK Technologies delivers first shipment of BKR 9000 radio to U.S. Army base - BK Technologies has delivered its first shipment of the BKR 9000 multiband radio to a U.S. Army Base located in the continental United States, as part of the base's portable communications technology lifecycle replacement program. The BKR 9000 radio is the Company's first multiband portable radio for the public safety market, providing high performance all-band coverage at a cost-efficient price point.

08:48 EDT Eskay Mining, Seabridge Gold terminate cost sharing agreement - Eskay Mining Corp. (ESKYF) announces that, further to its News Release of November 12, 2021, Eskay, Seabridge Gold Inc. (SA) and Seabridge's wholly-owned subsidiary, KSM Mining ULC, have signed an agreement to terminate the amended agreement whereby Seabridge and Eskay were to fund the costs of construction of the first 9 kilometres of the Coulter Creek Access Road, estimated to cost $12.5 million, with a limit on Eskay's contribution to a maximum of $6,250,000. Seabridge provided Eskay with a $3 million revolving loan facility at an interest rate of 3% per year to give Eskay flexibility with funding its share of the costs of construction. At the end of 2022, the costs incurred in respect of the construction of the First Segment of the CCAR were approximately $6 million. Seabridge had suspended delivering cash calls before year end and Eskay's share of cash calls to year end was funded through the drawdown of approximately $2.7 million of the loan facility provided by Seabridge pursuant to the Amended Cost Sharing Agreement. Seabridge completed 3.2 km of the road in 2022 and due to Seabridge concentrating its current road building activities on its Treaty Creek Access Road, it is uncertain when Seabridge will complete the First Segment of the CCAR. Eskay will not have access to or use of the First Segment of the CCAR for its 2023 exploration program. Therefore, Eskay, Seabridge and KSM agreed to terminate the Amended Cost Sharing Agreement and release each other from all obligations under the Amended Cost Sharing Agreement including any obligations relating to the completion of the First Segment of the CCAR, any obligation of Eskay to contribute to construction costs relating to the First Segment of the CCAR or any obligation of Seabridge to provide further loans or of Eskay to repay loans provided by Seabridge, or interest thereon. In addition, the 500,000 Bonus Warrants issued to Seabridge were cancelled. Pursuant to the terms of the Termination and Mutual Release Agreement, Eskay will have the right after completion of the First Segment of the CCAR, as long as KSM or its assignee operates the relevant CCAR segment, to request a road use agreement for the use of the First Segment of the CCAR. Pursuant to the terms of the road use agreement, Eskay will be required to pay an industry standard portion of maintenance costs and $100,000 per year for up to eight years for use of the First Segment of the CCAR.

08:45 EDT Recruiter.com CEO Evan Sohn steps down, Miles Jennings succeeds - Evan Sohn, the current CEO of Recruiter.com, has stepped down from the CEO position, effective June 2, 2023. However, he will remain active within the Company as Executive Chairman, focusing on strategic ventures including the closing of the GoLogiq business combination and the orchestrated spinout of the AI Company. Miles Jennings, a co-founder and the current President and COO of Recruiter.com, has assume the CEO role indefinitely.

08:43 EDT Orchestra BioMed appoints Andrew Taylor as CFO, succeeding Kaswan - Orchestra BioMed Holdings announced the appointment of Bill Little as EVP of Corporate Development and Strategy and Andrew Taylor as CFO. Mr. Taylor succeeds former CFO Michael Kaswan, who will continue as a consultant to the Company during a transition period."It's an honor to welcome Bill and Andrew to our executive team, two highly experienced medical device industry executives with a strong appreciation for our partnership-driven innovation and growth strategy," said David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed. "Bill brings an extraordinary depth of knowledge, expertise and relationships in the cardiovascular device industry that we believe will help us identify further opportunities to apply our business model for bringing medical innovations to life. Andrew and I have a long-standing professional relationship spanning more than six years, during which time he has proven to be a talented financial leader with highly relevant operational, capital markets and strategic perspective and experience. We look forward to generating additional value for our stakeholders with the aid of Bill and Andrew's leadership. We are also very grateful to Mike for his many contributions, which helped us build a strong balance sheet to adeptly enter the public markets."

08:41 EDT Nascent Biotech presents Phase I data on pritumumab at ASCO meeting - Nascent Biotech presented their Phase I Clinical Data at the American Society of Clinical Oncology meeting in Chicago in a poster presentation. "The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients," stated Dr. Mini Gill who presented for the Company. Nascent Biotech therapeutic antibody Pritumumab is a natural human antibody. This monoclonal antibody targets cell surface Vimentin, shown to be expressed on the surface of epithelial cancers. PTB is a targeted immunotherapy that binds to the tumor via cell surface vimentin and recruits the host immune system to eliminate cancer cells.

08:39 EDT Recon Technology awarded $1.0M contract for project in China - Recon Technology announced that Nanjing Recon Technology has been awarded a contract worth RMB 6,104,000, or $1.0M, for the Ground Control Project in the Deep Shale Gas Field at a Well Area in Chongqing City located in mainland China. The Company will commence the project upon contract execution and expects to complete services no later than December 31, 2024. Under the terms of the contract, Nanjing Recon will implement the Ground Control Project, which focuses on the autonomous monitoring and control system for the deep shale gas field. This project marks another significant milestone for Recon, and further solidifying its position as a key player in providing innovative solutions to the oil and gas industry in China.

08:36 EDT Artelo Biosciences to report research findings on ART12.11 - Artelo Biosciences was selected for an oral presentation at the 33rd International Cannabinoid Research Society Symposium being held on June 24-29, 2023 in Toronto, Ontario, Canada, at the Marriott Downtown at CF Toronto Eaton Centre. Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo's patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT. Results from preclinical studies with ART12.11 in stress-induced anxiety and depression that were conducted at the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada, will be presented by Professor O'Sullivan as well as data related to ART12.11's pharmacokinetics as compared to other forms of CBD. The medicinal potential of CBD has been established; however, because it is poorly absorbed there have been challenges related to the oral administration of CBD. Cocrystals are solid compositions designed to improve the physical characteristics of a drug, which can produce pharmaceutical, regulatory, and manufacturing advantages. To date, Artelo has been issued four patents on its cannabidiol cocrystal, including two patents from the U.S. Patent and Trademark Office and two foreign patents, related to ART12.11's composition and methods of use.

08:34 EDT Fr8App announces integration with Samsara - Freight Technologies announces a new integration with Samsara. With this integration, Fr8App customers can now leverage insights from Samsara's vehicle telematics solution, which includes real-time GPS tracking, advanced diagnostic reporting, and streamlined compliance management. This will help organizations optimize their logistics operations and ensure the timely delivery of their goods.

08:32 EDT Dirtt Environmental welcomes Empire Office to global Partner Network - DIRTT is welcoming Empire Office to its global Partner network. For over 75 years, Empire Office activates spaces by delivering all-inclusive architectural and custom-built solutions that help to bring their clients' brands to life.

08:31 EDT Amprius Technologies set to join Russell 3000 Index - Amprius Technologies is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted last month.

08:30 EDT SciSparc grants SciSparc Nutraceuticals exclusive license for CannAmide - SciSparc entered into a license and distribution agreement with SciSparc Nutraceuticals, a subsidiary in which the Company owns approximately a 51% equity interest, pursuant to which it granted SciSparc Nutraceuticals an exclusive license to sell and market CannAmide on the Amazon.com marketplace in Canada. CannAmide is an immediate unique palmitoylethanolamide oral formulation for the reduction of chronic pain and inflammation. CannAmide is currently available in tablet form, with each dose containing a 400mg active pharmaceutical ingredient. It has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate from Health Canada, for sale as a supplement within the nutraceuticals market. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties. SciSparc Nutraceuticals' business focusses on the sale of hemp seeds' oil-based products on the Amazon.com marketplace, under the brand Wellution. SciSparc Nutraceuticals plans on expanding its reach by marketing its brand's products in additional global markets and by broadening its products' offering. Pursuant to the License Agreement, the Company will sell to SciSparc Nutraceuticals CannAmide(TM) at a cost price plus 3% of gross revenues. The License Agreement is for a term of 12 months and may be terminated by either party with 30-days' advance notice. The License Agreement also contains customary representations, warranties, covenants and indemnification provisions.

08:28 EDT Jeffs' Brands reports SciSparc Nutraceuticals granted license for CannAmide - Jeffs' Brands (JFBR) announced that SciSparc Nutraceuticals, in which the Company owns a 49% equity interest, has entered into an exclusive license and distribution agreement to sell and market CannAmide on the Amazon.com marketplace in Canada. The exclusive license was granted by SciSparc (SPRC). CannAmide is an immediate unique palmitoylethanolamide oral formulation for the reduction of chronic pain and inflammation. CannAmide is currently available in tablet form, with each dose containing a 400mg active pharmaceutical ingredient. It has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate from Health Canada, for sale as a supplement within the nutraceuticals market. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties. SciSparc Nutraceuticals' business focusses on the sale of hemp seeds' oil-based products on the Amazon.com marketplace, under the brand Wellution. SciSparc Nutraceuticals plans on expanding its reach by marketing its brand's products in additional global markets and by broadening its products' offering. Pursuant to the License Agreement, SciSparc Nutraceuticals will purchase CannAmide at a cost price plus 3% of gross revenues. The License Agreement is for a term of 12 months and may be terminated by either party with 30-days' advance notice. The License Agreement also contains customary representations, warranties, covenants and indemnification provisions.

08:25 EDT OceanPal to effect 1-for-20 reverse stock split on June 8 - OceanPal announced its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common shares, par value $0.01 per share. The Company's shareholders approved the reverse stock split at the Company's annual meeting of shareholders held on May 3, 2023. The reverse stock split will take effect, and the Company's common shares will begin trading on a split-adjusted basis on NASDAQ, as of the opening of trading on June 8, 2023, under the existing trading symbol "OP". The CUSIP number of Y6430L202 will be assigned to the Company's common shares when the reverse stock split becomes effective. When the reverse stock split becomes effective, every twenty of the Company's issued common shares will be combined into one issued common share, without any change to the par value per share and without any change in the total number of authorized common shares. The number of outstanding common shares will be reduced from approximately 25,183,996 shares to approximately 1,259,199 shares.

08:23 EDT Voip-Pal files for dismissal of suits against Google, Facebook, Twitter - VoIP-Pal.com (VPLM) has filed stipulations with Facebook (META), Google (GOOG, GOOGL), and Twitter dismissing the lawsuits against these parties in the Northern District of California. Emil Malak, CEO of VoIP-Pal, stated, "With the California cases behind us we can now turn our full attention to the existing lawsuits in the Western District of Texas.Our desire has never been to litigate; legal action was always an option of last resort. However, as a small company trying to protect our intellectual property rights and the interests of our shareholders, we are prepared to go to trial against T-Mobile and Verizon in October. The patent litigation process can be very daunting for a small company like VoIP-Pal. We reluctantly began taking legal action in 2016, which resulted in our filing lawsuits against some of the world's largest corporations who have a combined market capitalization of more than seven trillion dollars. The list of our past and present defendants includes Apple, AT&T, Twitter, Amazon, Facebook, Google, Verizon, T-Mobile, Samsung, and Huawei. Despite sometimes feeling like a tiny mouse taking on a herd of elephants, we have persevered through it all. Patience is a virtue."

08:17 EDT EVmo enters LOI to merge with Micromobility.com - EVmo (YAYO) announced it has signed a Letter of Intentregarding a merger with micromobility.com (MCOM), a global micromobility ecosystem. The merger is intended to strengthen each company's market position and accelerate growth. The LOI outlines the general terms and conditions for a proposed merger, whereby EVMO would merge with a newly-formed subsidiary of micromobility.com and receive micromobility.com stock in a stock-for-stock exchange. It is expected that the current EVmo shareholders will receive a meaningful minority interest in the combined company. The parties agree to negotiate in good faith toward the execution of definitive transaction agreements, including a merger agreement setting forth the exchange ratio and the other terms and conditions of the transactions contemplated by the LOI, and a proxy statement/registration statement on Form S-4 registering with the SEC the shares to be issued as well as the solicitation of proxies for EVmo's shareholders to approve the merger. The definitive agreements are expected to be entered into within 30 days after signing this LOI, with the merger occurring promptly following satisfaction of the conditions thereto. The proposed merger is subject to several conditions, including the negotiation and execution of the definitive agreements, approval of the board of directors of each party and the shareholders of EVmo, each party's completion and satisfaction with the result of its due diligence investigations, approvals and agreements regarding indebtedness and other matters, absence of any material adverse change affecting either party, and receipt of SEC clearance regarding the Form S-4. The parties have agreed to certain limitations for a period of 30-60 days on negotiating with other parties concerning any transaction that would result in the issuance of more than 49% of the voting equity of such party.

08:14 EDT The Oncology Institute acquires Southland Radiation Oncology Network - The Oncology Institute has announced a strategic acquisition that aims to further consolidate the Greater Los Angeles market and establish the company as one of the largest value-based community oncology groups in the United States. The acquisition of Southland Radiation Oncology Network will amplify TOI's radiation oncology market presence by five additional clinics across the eastern San Gabriel Valley and Inland Empire, providing TOI with a distinct advantage over local private practices and tertiary centers. The company said, "The acquisition of SRON is an important milestone for TOI as they continue to expand their ability to provide complete population health for oncology care. It will enable broader coverage across the Los Angeles area, providing more access to life-saving care for those who may not be able to otherwise afford treatment or transportation. The acquisition of SRON will enable TOI to offer value-based radiation oncology care to more patients in the Greater Los Angeles area."

08:11 EDT Apollo reports ATLAS SP, ABF Franchise receives commitments from ADIA - Apollo announced that its newly established Asset-Backed Finance franchise and ATLAS SP Partners have received cornerstone capital commitments from a wholly owned subsidiary of the Abu Dhabi Investment Authority. ATLAS SP Partners is a securitized credit origination business majority owned by Apollo affiliates. ADIA's commitment to ATLAS SP will bolster its capacity to provide warehouse financing solutions. Typically investment grade credit risk, warehouse financing provided by ATLAS SP and large money-center banks supports mortgage originators, commercial finance providers and other specialty finance platforms helping companies and consumers to access credit. Inclusive of ADIA's commitment, ATLAS SP is expected to be able to support approximately $15 billion of new warehouse financing commitments, in addition to the approximately $40 billion of commitments under management by ATLAS SP today.

08:09 EDT Teledyne FLIR Defense delivers 1,000th MTRS Inc II robot to U.S. Army - FLIR Defense, part of Teledyne Technologies Incorporated, recently delivered the 1,000th robot under its Man Transportable Robot System Increment II contract with the U.S Army and other services. "We are honored that this versatile robot has become the most widely produced tactical unmanned ground vehicle used by America's military since the Gulf Wars," said Dr. JihFen Lei, executive vice president and general manager of FLIR Defense.

08:09 EDT Enveric Biosciences announces two poster presentations at CSC 2023 - Enveric Biosciences announced that its research involving the synthesis of small molecule derivatives of psychoactive compounds has been featured in two poster presentations at the Canadian Chemistry Conference and Exhibition being held in Vancouver June 4-8, 2023. The first poster titled, "Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders," describes the chemical synthesis of Enveric's EVM201 Series molecules to identify novel prodrugs of psilocin with altered metabolic profiles and reduced pharmacological exposure aimed at reducing the duration of the psychedelic experience. Beginning with 30 unique molecules, representing nine distinct prodrug classes, 15 candidates were selected that released the highest levels of psilocin in vitro. Pharmacokinetic analysis confirmed that the efficient release of psilocin in vitro correlated with the amount of psilocin detected in blood plasma. Two molecules that produced plasma psilocin concentrations comparable or superior to psilocybin were evaluated for long-term anxiolytic benefit in chronically stressed mice using the marble-burying psychiatric model. The second poster titled, "Design, synthesis and pharmacological evaluation of novel MDMA derivatives as potential therapies for the treatment of psychiatric conditions," describes the design and chemical synthesis of a library of 30 novel MDMA derivatives. The compounds were tested for their ability to bind serotonin receptors and transporters. The results show how modifications to the chemical structure of MDMA can lead to substantial alteration in binding to different serotonin receptors and transporters, which could alter pharmacological properties.

08:08 EDT Alight names Gregory George as chief commercial officer for NA ES business - Alight announced Gregory George has been named Alight's chief commercial officer for its North America Employer Solutions business. Greg will be responsible for accelerating Alight's North America growth strategy and leading all aspects of its commercial organization, including sales, strategic accounts, channels and partnerships. He will report to CEO, Stephan Scholl.

08:06 EDT Ocular Therapeutix completes enrollment in HELIOS trial of OTX-TKI - Ocular Therapeutix announced completion of enrollment in the HELIOS clinical trial of OTX-TKI. Using Elutyx technology, OTX-TKI is the Company's axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.Diabetic retinopathy is a leading cause of vision loss in working-age adults, affecting approximately 140 million individuals around the world, including 8.4 million people in the United States alone. Diabetic retinopathy can lead to vision loss and even blindness due to high levels of blood sugar in the eyes that damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye.

08:05 EDT Thoughtworks appoints Mike Mason as Chief AI Officer - Thoughtworks announced the appointment of Mike Mason as Chief Artificial Intelligence Officer. Mason will report to Thoughtworks' Chief Technology Officer, Rachel Laycock. In this new global role, Mason will guide clients through their generative AI journeys and accelerate their adoption of this new technology.

08:04 EDT SMX enters into a 120 day exclusive agreement with Sunshine Minting - SMX announced that it is in the process of creating a new subsidiary, trueSilver, and has entered into a 120 day exclusive agreement with Sunshine Minting, to create a path to full transparency and traceability for silver products from mine site to final products and recycling and the creation of an industry standard. This announcement follows the successful filing of patents pertaining to gold, aluminum, steel and cobalt in 2023. With silver rarely being found in its pure form and at least 80% of the world's silver being produced as a by-product of mining for other metals such as gold, copper, lead and zinc, this progression is considered by SMX to be the natural next step. Metals Focus and The Silver Institute forecasted in the "World Silver Survey 2022", the total supply to be 1,030.0M ounces in 2022, up from 997.2M ounces in 2021, with the 2022 total demand equaling 1,101.8M ounces, up from 1,049.0M ounces in 2021.

08:03 EDT DermTech announces contract with Hawaii Blues plan - DermTech announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test for the nearly 800,000 members of this plan, DermTech said in a statement. DermTech's total covered lives in the U.S. are approximately 126 million, which includes 68 million for Medicare/Medicare Advantage and 58 million for commercial and governmental payers.

08:02 EDT ViaSat selected by Air Force Research Laboratory - Viasat announced it was selected by the Air Force Research Laboratory, or AFRL, Space Vehicles Directorate, or RV, to provide on-orbit space relay connectivity for its ARBALEST program, which aims to support a future space-based demonstration of operational capabilities for the Department of Defense, or DoD. The future AFRL mission will illustrate the advantages of enabling real-time, global connectivity between DoD low Earth orbit, or LEO, spacecraft and commercial geostationary, or GEO, satellites. The ARBALEST program and expected AFRL-led mission will demonstrate the military utility of LEO space relay over commercial high throughput satellites in support of space mission resilience, real-time data dissemination, command and control, or C2,as well as the rapid retasking of government space vehicles. Viasat's space relay solution is key to enabling these capabilities and will leverage the upcoming ViaSat-3 constellation, which includes three Ka-band terabit-class GEO satellites, to provide continuous coverage for LEO spacecraft anywhere and at any time in their orbit. Under the ARBALEST program, Viasat will provide AFRL with a Ka-band space relay payload for integration into a spacecraft for the future AFRL mission, as well as provide engineering analysis, integration and test support. Viasat will also support the on-orbit demonstration phase of the mission.

08:01 EDT Wayfair reports quarter-to-date gross revenue is strengthening - Wayfair shared that quarter-to-date gross revenue is strengthening, and is now trending in the negative mid single digit percentage range year-over-year. This improvement relative to the company's last business update has been driven by total order growth turning positive year-over-year during the period, offsetting lower average order values and the impact of deflation.

07:53 EDT Mercedes-Benz, H2 Green Steel secure supply deal, MOU - Mercedes-Benz signed a supply agreement with Swedish start-up H2 Green Steel over approximately 50,000 tonnes almost CO2-free steel per year for its European press shops and deepened its partnership through a Memorandum of Understanding with the aim to establish a sustainable steel supply chain in North America. After taking an equity stake in H2GS in 2021, the new supply agreement enables Mercedes-Benz to bring almost CO2-free steel into series production. The partner plans to start its production during 2025.

07:37 EDT Aligos to present posters highlighting data on liver disease program at EASL - Aligos Therapeutics announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver EASL Congress 2023, taking place in Vienna, Austria, June 21 - 24. "These presentations highlight the progress we have made advancing new potentially best-in-class compounds," said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. "Each of these compounds represent a novel therapeutic strategy and we look forward to reporting additional findings at future meetings."

07:32 EDT Dragonfly Energy speaks at Rho Motion Seminar Series - Dragonfly Energy Holdings Director of Research and Development, Dr. Vickrum Singh, joined a panel of experts from the energy storage, EV, charging and infrastructure, lithium battery recycling, and battery materials markets at the Rho Motion Seminar Series in New York late last month. Dr. Singh addressed Dragonfly Energy's technology in the lithium battery storage sector and the Company's patented cell manufacturing technology. Dr. Singh provided insights into the different aspects of successful lithium battery cell production, from development to testing to full production and how the Dragonfly Energy solution of manufacturing these cells results in a cleaner, less costly process that can be accomplished within a significantly reduced manufacturing footprint when compared to a traditional cell manufacturing line.

07:31 EDT Organon, CAF launch collaboration to increase sustainable financing - Organon and CAF, Development Bank of Latin America, signed a memorandum of understanding to contribute to the United Nations Sustainable Development Goals "through the design, structure and implementation of sustainable programs that promote and improve equity, health and autonomy of girls and women in Latin America and the Caribbean." "At Organon, we believe that results-based financing can drive collective action to progressing women's health goals," said Kevin Ali, Organon CEO.

07:22 EDT Cibus has test results demonstrating resistance of Sclerotinia in canola - Cibus announced that it had additional greenhouse test results demonstrating successful resistance against White Mold or Sclerotinia in canola. This greenhouse tests showed both an enhanced and an additional mode of action from previously reported field trial results of the Cibus Sclerotinia resistance trait. Together, these two different modes of action provide an increased level of resistance against Sclerotinia than each alone. The core of Cibus' gene editing technology is its Rapid Trait Development System or RTDS . It is a system of proprietary technologies that integrate crop specific cell biology platforms with a series of gene editing technologies. RTDS enables the Trait Machine a stand-alone semi-automated end-to-end precision breeding system whose traits are indistinguishable from conventional breeding. Together with the Trait Machine , RTDS allows for the successful development of these traits and the ability to address multiple modes of action.

07:20 EDT Campbell Soup: FY23 adjusted EPS tracking to upper end of guidance range

07:19 EDT Aldebaran Resources reports results from holes at Altar copper-gold project - Aldebaran Resources reports results for holes ALD-23-227 and ALD-23-228 from its ongoing drilling campaign at the Altar copper-gold project in San Juan Province, Argentina. Hole ALD-23-227 was a 200 m step out hole to the north from previously released ALD-22-223. ALD-23-228 was a 200 m step out to the north from previously released ALD-23-225B. Both holes have provided valuable additional pierce points into the promising geophysical anomaly beneath and lateral to current resources at the Altar project. In addition, both ALD-23-227 and ALD-23-228 tested the northern extension of the newly identified Altar United trend. ALD-23-227 entered favourable host rocks at approximately 1,000 m depth, and then returned attractive grade mineralization until the end of the hole. ALD-23-228 hit the favourable host rock formation at approximately 750 m depth and thereafter returned some of the highest-grade copper mineralization encountered on the project to date, demonstrating that the high-grade mineralization found previously in hole ALD-23-225B has continuity. Highlights: ALD-23-228: 565.60 m of 0.60% CuEq from 676.00 m depth, Including 474.60 m of 0.69% CuEq from 767.00 m depth, Including 329.60 of 0.80% CuEq from 912.00 m depth, Including 58.00 m of 1.02% CuEq from 1,011.00 m depth; Hole ended in 74.60 m of 0.80% CuEq with the last sample running 0.96% CuEq; The Company has re-entered hole ALD-23-228 and is actively drilling to test for the deeper extension of this higher-grade mineralization. ALD-23-227: 198.50 m of 0.50% CuEq from 1,040.00 m depth. Including 60.50 m of 0.63% CuEq from 1,178.0 m depth; Hole ended in 31.50 m of 0.69% CuEq. John Black, CEO, commented: "Hole 228 represents another remarkable run of mineralization and represents some of the better grades we've seen at the Altar project. We have re-started drilling on hole 228 to see if the higher-grade mineralization continues to depth. The Altar system continues to grow well beyond what was previously understood. The resource we have in hand already represents one of the largest undeveloped copper projects in the world; however, with the mineralization we've been hitting in recent drill results, we expect it to grow substantially."

07:16 EDT Lovesac CSO Jack Krause retires - The Company announced today that Jack Krause has retired from his role as Chief Strategy Officer effective June 30, 2023 and will remain a member of the Company's board of directors. Jack's current responsibilities will be divided between CEO Shawn Nelson and Mary Fox, President and COO.

07:14 EDT Canadian Solar unit, CSI Solar Co., to be listed on Shanghai Stock Exchange - Canadian Solar announces that its majority-owned subsidiary CSI Solar Co., will be listed on Shanghai Stock Exchange's Sci-Tech Innovation Board on June 9 under the stock code 688472. The shares of CSI Solar will not be and have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

07:13 EDT Tonix Pharmaceuticals announces data presentations on TNX-1500 - Tonix Pharmaceuticals announced data from two oral presentations and one poster presentation at the 2023 American Transplant Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix's TNX-1500 in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand, which is also known as CD154. Copies of the presentations are available on the Tonix Pharmaceuticals website at www.tonixpharma.com. The oral presentations titled, "Fc-Modified anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications" by Dr. Ryo Otsuka et al. and "Efficacy of CD154 Blockade with TNX-1500 to prevent heart allograft immune injury" by Dr. Ikechukwu Ileka et al., and the poster presentation titled "anti-CD154 mAb Alone, or in Combination with Rapamycin, MMF, or anti-CD28 mAb Prolongs Cynomolgus Cardiac Allograft Survival" by Dr. Kohei Kinoshita et al. include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates. Blockade of CD40L with TNX-1500 monotherapy consistently prevented pathologic alloimmunity in non-human primate kidney and cardiac allograft models without clinical thrombosis. Dr. Kinoshita was recognized with "Poster of Distinction" for his poster presentation. "The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function, which we believe provides strong rationale for us to pursue development of TNX-1500 to prevent rejection in human transplant," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We expect to begin a Phase 1 trial with TNX-1500 in the third quarter of 2023. There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease FcgammaRII binding and to reduce the potential for thrombosis. We believe TNX-1500 has the potential for treating and preventing organ transplant rejection. Beyond transplantation, we believe TNX-1500 has potential for treating autoimmune conditions including systemic lupus erythematosus, Sjogren's syndrome and multiple sclerosis."

07:11 EDT Intercept announces new data on fixed-dose combination of OCA, bezafibrate - Intercept Pharmaceuticals announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic potential of the combination of obeticholic acid and bezafibrate vs. bezafibrate monotherapy on serum biomarkers in primary biliary cholangitis. These data are part of a larger analysis that will be presented at 08:45 CEST on Friday, June 23 at the European Association for the Study of the Liver Congress 2023 in Vienna, Austria. Data will be presented from the planned interim analysis of patients with PBC who were randomized 1:1:1:1 to receive 12 weeks of once-daily oral therapy in addition to ongoing UDCA treatment in one of four treatment arms: bezafibrate 200 mg; bezafibrate 400 mg; bezafibrate 200 mg + OCA 5 mg titrated to 10 mg at week 4; bezafibrate 400 mg + OCA 5 mg titrated to 10 mg at week 4; Endpoints included serum biomarkers of PBC-induced liver damage such as alanine transaminase and aspartate aminotransferase as well as markers shown to predict transplant-free survival such as alkaline phosphatase, gamma-glutamyl transferase and total bilirubin. Safety was assessed by monitoring of adverse events and laboratory values. As reflected in the abstract and available on the EASL website, data from the first 45 patients enrolled in Study 213 showed that over half of those receiving OCA5-10/B400 rapidly achieved normal range ALP at 4 weeks with continued improvement through week 12. In addition, patients randomized to OCA5-10/B400 exhibited the highest rates of biomarker normalization at week 12: ALP, total bilirubin, ALT, and GGT. Low rates of AEs were observed, with a majority considered mild and not related to study drug. Rates of pruritus were 25% or less in any treatment arm. Four patients in the study experienced severe or serious treatment-emergent AEs, all deemed not study-drug related. Intercept has two ongoing Phase 2 studies that are exploring a range of therapeutic doses for the combination of OCA and bezafibrate. Intercept expects to complete planned interim analyses from both ongoing Phase 2 studies this year. Analyses from these Phase 2 studies, in addition to Phase 1 and preclinical data, will serve as the basis of an end-of-phase 2 meeting with FDA.

07:08 EDT Fiserv completes listing transfer to NYSE - Fiserv, Inc. announced that it has completed the transfer of its stock exchange listing to the New York Stock Exchange. Effective today the company begins trading under the ticker symbol "FI."

07:07 EDT Enanta presenting preclinical data at EASL 2023 - Enanta Pharmaceuticals announced that preclinical data from Enanta's out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver International Liver Congress 2023 being held June 21 - 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre. In the poster, Enanta's HSD17B13 inhibitors, which have previously been shown to be anti-inflammatory in vivo with modulation of sphingolipids, were evaluated in a mouse model of autoimmune hepatitis for anti-inflammatory and hepatoprotective effects.

07:05 EDT Atlas Technical Consultants opens Denver hub - Atlas Technical Consultants has expanded its footprint with the opening of a new hub office in Denver, Colorado. The new hub will serve as the growth and service provider for the Mountain Region. All four of our service lines, Testing, Inspection, and Certification; Program Management/construction Management and Quality Management; Engineering & Design; and Environmental Solutions will be provided from this location. This HUB will strengthen Atlas' goal to provide client-centric services to strengthen critical infrastructure and environmental resources that sustain communities.

07:04 EDT AbbVie announces reimbursement for VRAYLAR under NIHB program - AbbVie announced that VRAYLAR is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits program for the treatment of schizophrenia. This announcement comes 13 months after the authorization of VRAYLAR by Health Canada, bringing an additional treatment option to Canadians living with schizophrenia.

07:03 EDT Wayfair names Jon Blotner as Chief Commercial Officer - Wayfair shared an update on its business leadership and performance. The company announced that Steve Oblak, Chief Commercial Officer, will retire from Wayfair in Q1 2024 after 14 years of leadership. It announced the planned appointment of Jon Blotner to the role of Chief Commercial Officer and also shared details on quarter-to-date business trends, which continue to improve in spite of a difficult macro environment. Wayfair Names Jon Blotner Incoming Chief Commercial Officer. Jon Blotner brings to the CCO role nearly two decades of experience growing retail businesses, technology offerings and services while also building, operating and scaling high-performing teams across a diverse range of functions. To date at Wayfair, he has overseen the company's Exclusive Brands and Specialty Retail Brands, which include AllModern, Joss & Main and Birch Lane, as well as its Visual Media, 3D Operations and Technology, Merchandising as a Service, Advertising, and Supplier Acquisition and Onboarding functions. Before joining Wayfair, Jon served as President of Gemvara.com until it was acquired by Berkshire Hathaway in 2016. Prior to Gemvara, Jon worked for Bain & Company in Boston. Blotner will serve as Incoming CCO beginning July 2023 and will formally assume the CCO role in October.

07:02 EDT Palantir, Panasonic Energy of North America enter multi-year agreement - Palantir Technologies announced a multi-year partnership to deliver an operations "Smart Factory" for the Panasonic Energy of North America facility in Sparks, Nevada. The company has selected Palantir's Foundry to help integrate edge sensors across factory lines, introduce automated efficiencies and enable operational users on factory floors to leverage connected operations. The agreement expands Palantir's signature platform including artificial intelligence and edge capabilities in the manufacturing space. Driven by Foundry and informed by PENA's expertise, the "Smart Factory" will be utilized across the entirety of the information technology and operational organization within PENA. Using Foundry, the system will guide operational decision-making in their existing Nevada factory as well as the new facility in De Soto, Kansas starting in 2025. This strategic partnership is intended to provide the battery leader with the ability to quickly generate meaningful cost savings and increase return on investment once implemented.

06:57 EDT TreeHouse to acquire Farmer Bros. Texas coffee facility for $100M - TreeHouse Foods (THS) announced that it has signed a definitive agreement with Farmer Brothers Company (FARM) to acquire its Northlake, Texas, coffee facility and the Farmer Brothers non-Direct Store Delivery coffee business for approximately $100M, subject to customary purchase price adjustments. The facility, built in 2017, brings roasting, grinding, flavoring and blending capabilities to the TreeHouse Foods portfolio to complement the Company's existing single-serve pod and ready-to-drink coffee businesses. The acquisition enables TreeHouse Foods to deliver greater category depth in a world-class, end-to-end private label coffee offering for its customers. Farmer Brothers has historically been a bulk ground coffee supplier to TreeHouse Foods for its single-serve pods and ready-to-drink beverages. Following closing, the acquisition is expected to create greater profit capture in the supply chain. TreeHouse Foods will also assume select customer relationships and retain approximately 180 team members from Farmer Brothers to support operations at the facility. The transaction is expected to close within the next 60 days.

06:52 EDT UnitedHealth raises quarterly dividend 14% to $1.88 from $1.65 per share - The Board of Directors authorized a 14% increase to its quarterly cash dividend. A cash dividend of $1.88 per share, will be paid on June 27 to all shareholders of record of UNH common stock as of the close of business June 19. This dividend represents an increase over the quarterly dividend of $1.65 per share the company has paid since the second quarter of 2022.

06:45 EDT Diageo announces Sir Ivan Menezes has passed away - Diageo announces that Sir Ivan Menezes has passed away following a brief illness, with his family at his side. The company said: "During his decade as CEO, Ivan oversaw an outstanding period of change, growth and high performance. Diageo made huge strides towards his ambition that Diageo should become one of the best performing, most trusted and respected companies in the world." On Monday, Diageo appointed Debra Crew Interim CEO with immediate effect, ahead of her appointment as CEO and joining the Board as an executive director on July 1. Reference Link

06:32 EDT Sidus Space to launch LizzieSat satellite on SpaceX Transporter missions in 2024 - Sidus Space announced that it will launch industry leading hyperspectral and multispectral imaging and Edge Artificial Intelligence in its LizzieSat satellite on SpaceX Transporter missions beginning in 2024. LizzieSat's hyperspectral and multispectral imaging capability will be provided by the Owl 1280 and Hawk 1920 HD cameras made by Raptor Photonics. Sidus is building its space-based infrastructure of multi-mission satellites with hyperspectral, multispectral and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company plans to monetize its imagery both through previously negotiated contracts and through its agreement with Skywatch and others to sell imagery on their storefront. This hyperspectral and multispectral capability is also key to the Sidus' strategy to generate recurring revenue streams from new customers as Sidus builds its LizzieSat constellation. Sidus plans to launch its first LizzieSat on the SpaceX Transporter mission scheduled for later this year and has contracted with SpaceX to launch on four additional flights, with two currently scheduled for 2024 and two more scheduled for 2025, allowing the Company to establish a regular launch cadence for its customers. The Company plans to begin offering hyperspectral and multispectral imaging from its LizzieSats scheduled for launch on SpaceX's transporter mission in the first quarter of next year.

06:27 EDT AES Corp. acquires 2 GW Bellefield solar-plus-storage project - The AES Corporation announced the acquisition of the 2 GW Bellefield project, which is currently in late-stage development, and is the largest permitted solar-plus-storage project in the United States. The project, located in Kern County, California, where AES already has significant operations, includes two phases, each with 500 MW of solar and up to 500 MW of four-hour duration battery energy storage. The project represents a significant step in accelerating California's commitment to achieving 100% carbon-free energy by 2045. Phase one of the Bellefield project has a 15-year Power Purchase Agreement to deliver hourly, carbon-free energy to an existing AES corporate customer. AES expects to contract up to an additional 1 GW of solar-plus-storage in phase two of the Bellefield project by the end of 2023. The two phases of the project were developed by the seller, Avantus, and are expected to come online in 2025 and 2026, respectively.

06:05 EDT Aspen Aerogels opens Advanced Thermal Barrier Center in Massachusetts - Aspen Aerogels is celebrating the opening of its engineering and rapid prototyping facility in Marlborough, MA. Aspen's Advanced Thermal Barrier Center will be the engineering hub of PyroThin cell-to-cell barriers, which help manufacturers optimize the safety and performance of battery packs for eMobility and energy storage system markets. The opening of this 59,000-square-foot facility upholds Aspen Aerogels' commitment to supporting the growth of the electrification movement. As electric batteries continue improving to meet performance requirements, thermal runaway events dampen public acceptance of eMobility technology. PyroThin thermal barriers are at the forefront of thermal runaway propagation protection. . The Advanced Thermal Barrier Center highlights Aspen's dedication to a collaborative approach. Located 45 minutes outside Boston, global manufacturers can travel to the ATBC to collaborate with engineers in real time and take advantage of its rapid prototyping capabilities. In addition to customer-facing engineering services, the Advanced Thermal Barrier Center will also house the commercialization of the next generation of thermal runaway solutions.

06:03 EDT Marathon Digital appoints Salman Khan as CFO - Marathon Digital Holdings (MARA) announced the appointment of Salman Khan to the position of CFO. Khan brings to Marathon 25 years of finance and accounting experience. Prior to joining Marathon, he served as CFO for Verb Technology (VERB), a Nasdaq listed leading provider of interactive video-based software-as-a-service applications and an e-commerce platform. Prior to being appointed CFO, Khan held various roles at Verb including interim CFO, and executive vice president of corporate development and strategic planning. Before joining Verb, Khan served in various senior executive level positions at Occidental Petroleum and its spinoff, California Resources including director of renewable energy, director of corporate development, director of technical accounting and financial reporting, and business division controller and CFO. Khan also spent eight years at major accounting firms including Arthur Andersen, PricewaterhouseCoopers and Ernst & Young, where he served domestic and international clients in the technology, media, telecommunications, entertainment, and biotechnology industries. Khan holds a Master in Business Administration from the University of Michigan, Ross School of Business and is a licensed chartered certified accountant in the UK.

05:54 EDT KKR, Japan Post Insurance, Global Atlantic to form strategic partnership - Japan Post Insurance Co., KKR & Co, and Global Atlantic Financial Group announced their entrance into a strategic partnership. Japan Post Insurance will additionally make a material investment in a reinsurance co-investment vehicle sponsored by Global Atlantic. KKR and Global Atlantic's collective track records of delivering customized solutions for global life and annuity insurance clients is well-suited to helping advance Japan Post Insurance's growth strategy. The partnership enables Japan Post Insurance to access KKR and Global Atlantic's platforms to enhance its growth and diversify its business portfolio into overseas markets.

05:50 EDT Stellantis launches second tranche of share buyback program - Stellantis announced that pursuant to its Share Buyback Program announced on February 22, 2023, covering up to EUR1.5B to be executed in the open market with the intent to cancel the common shares acquired through the Program and following the completion of the first tranche of the Program as announced on May 18, 2023, Stellantis has signed a share buyback agreement for the second tranche of its Program with an independent investment firm that makes its trading decisions concerning the timing of purchases independently of Stellantis. This agreement will cover a maximum amount of up to EUR500M. The second tranche of the Program shall start on June 7, 2023 and end no later than September 7, 2023. Common shares purchased under the Program will be cancelled in due course.